Turkiye Klinikleri Journal of Medical Ethics-Law and History

.: RESEARCH
1950'li Yıllar ve Antidepresif Psikofarmakoterapi: Prototiplerinden Bugüne Klinik Antidepresanların Tasnif ve Tarihi
The 1950s and Antidepressive Psychopharmacotherapy: History and Classification of Clinical Antidepressants from Their Prototypes to Today
M. Kemal TEMELa
aTıp Tarihi ve Etik AD, İstanbul Üniversitesi İstanbul Tıp Fakültesi, İstanbul, TÜRKİYE
Turkiye Klinikleri J Med Ethics. 2019;27(2):89-102
doi: 10.5336/mdethic.2018-63817
Article Language: TR
Full Text
ÖZET
 Bugün, farklı farmasötik sınıflardan çeşitli antidepresif ajanlar klinik depresyon tedavisinde başarıyla kullanılmaktadır. Ne var ki Türkçe tıp literatüründe bu ilaçların güncel klinik kullanım ve sonuçlarına dair bol miktarda yayın bulunmasına karşın, bunların tarihi klinik gelişim sürecini kökenlere inerek, teferruatla bildiren çalışmalar çok azdır. Bu araştırmada, literatürdeki bu boşluğun dolduruluşuna katkıda bulunmak amaçlanmıştır. Araştırmada, antidepresif ajanların kısmen etki mekanizmalarına kısmen de kimyasal yapılarına göre düzenlenmiş olan klasik tasnifi izlenmiştir. PubMed ve ScienceDirect gibi veri tabanlarının ve çeşitli bilimsel dergilerin arşivlerinin retrospektif taranışı ile her bir farmasötik alt sınıfın başlangıcını teşkil eden prototipik antidepresanın keşfi; tarihi olay örgüsüne, ilgili tıbbi figürlere ve orijinal klinik araştırma sonuçlarına dair ilk elden bilimsel yayınlar üzerinden işlenmiştir. Antidepresif psikofarmakoterapi tarihindeki dönüm noktaları üzerinde durulmuş, başlıca ilaç sınıfları (monoamin oksidaz inhibitörleri, trisiklik ve tetrasiklik ajanlar ve monoaminerjik geri alım inhibitörleri) arasında bağlantılar kurulmuş ve yerine göre analojiler yapılmış ya da farklılıklar vurgulanmıştır. Varılan başlıca bir sonuç, antidepresif psikofarmakoterapi tarihinde tesadüfi gözlem eseri ("ilk kuşak/klasik") ajanlardan rasyonel dizaynla ilaç üretimine ("ikinci kuşak" antidepresanlara) geçişin interdisipliner iş birliğine borçlu olunan gelişmelerle mümkün olmuş olduğudur: Çeşitli bilimsel branşlardan kişilerce monoaminerjik konsantrasyon hipotezinin ortaya atılışı, monoamin oksidaz-A ve -B enzimlerinin keşfi, floresans mikroskopiye dayanan histokimyasal görüntüleme yönteminin geliştirilişi, antidepresif ajanların etki mekanizmalarının sistematik in vitro ve in vivo tetkikatla aydınlatılışı ve de antihistaminikler gibi mevcut kimyasalların ya da yeni maddelerin klinik çalışmalarla antidepresif potansiyelleri bakımından sınanışı gibi aşamalardan geçilerek, sonunda bugün majör depresif bozukluk tedavisinde başvurulan birincil ilaçlar olan monoaminerjik geri alım inhibitörlerine ulaşılmıştır.

Anahtar Kelimeler: Antidepresan; antidepresanların tarihi; fluoksetin; imipramin; iproniazid; klorpromazin; monoamin hipotezi; tarih
ABSTRACT
 Various antidepressive agents from different pharmaceutical classes are used successfully to treat depression today. Despite their well-documented clinical use and outcomes, however, the Turkish medical literatüre appears to lack studies dilating upon their historical development with reference to the origins and key events. Aimed at contributing to filling this gap, this study was built on the classical classification of antidepressive agents based partly on mechanism of action and chemical structure. PubMed, ScienceDirect, and various journal archives were reviewed retrospectively concerning the discovery of each agent that prototyped the pharmaceutical subclass investigated, with a focus on the timeline events, medical figures, and original clinical research results. The milestones in the history of antidepressive psychopharmacotherapy were highlighted, with connection and comparison between the main drug classes (monoamine oxidase inhibitors, tricyclics and tetracyclics, and monoaminergic reuptake inhibitors) through analogies and distinctions identified when appropriate. A main conclusion was that the consequential transition from the serendipitously obtained ("first-generation/classical") agents to rationally designed drug production (the "second-generation" antidepressants) was achieved by developments brought about by interdisciplinary collaboration. Production of the MRIs, pharmaceutics used primarily in treating major depressive disorder today, was processed through various stages by various scientific contributors propounding the monoaminergic concentration hypothesis, discovering the monoamine oxidase-A and -B enzymes, developing the histochemical visualization methodology by fluorescence microscopy, elucidating mechanisms of action of antidepressive agents through in vitro and in vivo investigation, and testing the existing chemicals such as antihistamines or new derivatives in clinical studies for their antidepressive potentials.

Keywords: Antidepressant; history of antidepressants; fluoxetine; imipramine; iproniazid; chlorpromazine; monoamine hypothesis; history
REFERENCES:
  1. Charpentier P, Gailliot P, Jacob R, Gaudechon J, Buisson P. Recherches sur les diméthylaminopropyl-N phénothiazines substituées. C R Acad Sci. 1952;235:59-60.
  2. Laborit H, Huguenard P, Alluaume R. [A new vegetative stabilize ; 4560 R.P]. Presse Med. 1952;60(10):206-8.
  3. Delay J, Deniker P, Harl JM. [Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP)]. Ann Med Psychol (Paris). 1952;110(2 1):112-7.
  4. Delay J, Deniker P, Harl JM. [Therapeutic method derived from hiberno-therapy in excitation and agitation states]. Ann Med Psychol (Paris). 1952;110(2 2):267-73.
  5. Delay J, Deniker P, Harl JM, Grasset A. [N-dimethylamino-prophylchlorophenothiazine (4560 RP) therapy pf confusional states]. Ann Med Psychol (Paris). 1952;110(2 3):398-403.
  6. Delay J, Deniker P. Le traitement des psychoses par une méthode neurolytique dérivée de l?hibernothérapie (le 4560 RP utilisé seul en cure prolongée et continue). Comptes Rendus du 50 Congrès des Médecins Aliénistes et Neurologistes de Langue Française (22-26.7.1952). Paris: Masson & Cie; 1952. p.495-502.
  7. Delay J, Deniker P. Trente-huit cas de psychoses traitées par la cure prolongée et continué de 4560RP. Comptes Rendus du 50 Congrès des Médecins Aliénistes et Neurologistes de langue Française (22-26.7.1952). Paris: Masson & Cie; 1952. p.503-13.
  8. Delay J, Deniker P. Réactions biologiques observées au cours du traitement par le chlorte de deméthylaminoprppyl-Nchlorophénothiazine. Comptes Rendus du 50 Congrès des Médecins Aliénistes et Neurologistes de Langue Française (22-26.7.1952). Paris: Masson & Cie; 1952. p.514-8.
  9. Lehmann HE. Selective inhibition of affective drive by pharmacological means. Am J Psychiatry. 1954;110(11):856-7. [Crossref]
  10. Lehmann HE, Hanrahan GE. Chlorpromazine; new inhibiting agent for psychomotor excitement and manic states. AMA Arch Neurol Psychiatry. 1954;71(2):227-37. [Crossref]
  11. Stip E. Who pioneered the use of antipsychotics in North America? Can J Psychiatry. 2015;60(3 Suppl 2):S5-13.
  12. Kline NS. Use of Rauwolfia serpentina Benth. In neuropsychiatric conditions. Ann N Y Acad Sci. 1954;59(1):107-32. [Crossref] [PubMed]
  13. Barsa JA, Kline NS. Treatment of two hundred disturbed psychotics with reserpine. J Am Med Assoc. 1955;158(2):110-3. [Crossref]
  14. Kline NS, Stanley AM. Use of reserpine in a neuropsychiatric hospital. Ann N Y Acad Sci. 1955;61(1):85-91. [Crossref]
  15. Barsa JA, Kline NS. Use of reserpine in disturbed psychotic patients. Am J Psychiatry. 1956;112(9):684-91. [Crossref] [PubMed]
  16. Barsa JA, Kline NS. Combined reserpinechlorpromazine in treatment of disturbed psychotics. AMA Arch Neurol Psychiatry. 1955;74(3):280-6. [Crossref]
  17. Barsa JA, Kline NS. A comparative study of reserpine, chlorpromazine, and combined therapy. AMA Arch Neurol Psychiatry. 1956;76(1):90-7. [Crossref]
  18. The Albert and Mary Lasker Foundation. 1957 Albert Lasker Clinical Medical Research Award: chlorpromazine for treating schizophrenia. Erişim: 8.1.2017. [Link]
  19. Newbould BB. The future of drug discovery. In: Walker BC, Walker SR, eds. Trends and Changes in Drug Research and Development. 1st ed. Dordrecht: Kluwer Academic Publishers; 1988. p.109. [Crossref]
  20. Ramachandraih CT, Subramanyam N, Bar KJ, Baker G, Yeragani VK. Antidepressants: from MAOIs to SSRIs and more. Indian J Psychiatry. 2011;53(2):180-2. [Crossref] [PubMed] [PMC]
  21. Selikoff IJ, Robitzek EH. Tuberculosis chemotherapy with hydrazine derivatives of isonicotinic acid. Dis Chest. 1952;21(4):385-438. [Crossref]
  22. Selifoff IJ, Robitzek EH, Ornstein GG. Toxicity of hydrazine derivatives of isonicotinic acid in the chemotherapy of human tuberculosis; a preliminary report. Q Bull Sea View Hosp. 1952;13(1):17-26.
  23. Robitzek EH, Selifoff IJ, Mamlok E, Tendlau A.Isoniazid and its isopropyl derivative in the therapy of tuberculosis in humans: comparative therapeutic and toxicologic properties. Dis Chest. 1953;23(1):1-15.[Crossref] [PubMed]
  24. The Albert and Mary Lasker Foundation. 1955 Albert Lasker Clinical Medical Research Award: isoniazid for treating tuberculosis. Erişim: 8.1.2017. [Link]
  25. Salzer HM, Lurie ML. Anxiety and depressive states treated with isonicotinyl hydrazide (isoniazid). AMA Arch Neurol Psychiatry. 1953;70(3):317-24. [Crossref]
  26. Kamman GR, Freeman JG, Lucero RJ. The effect of 1-isonicotynl 2-isopropyl hydrazide (IIH) on the behavior of long-term mental patients. J Nerv Ment Dis. 1953;118(5):391-407. [Crossref] [PubMed]
  27. Delay J, Laine B, Buisson JF. [The action of isonicotinly-hydrazide used in the treatment of depressive states]. Ann Med Psychol (Paris). 1952;110(2 5):689-99.
  28. Smith JA. The use of the isopropyl derivative of isonicotinylhydrazine (marsilid) in the treatment of mental disease; a preliminary report. Am Pract Dig Treat. 1953;4(8):519-20.
  29. Healy D. The Creation of Psychopharmacology. Cambridge (MA/ABD): Harvard University Press; 2002. p.56.
  30. Noll R. Antidepressant drugs. In: The Encyclopedia of Schizophrenia and Other Psychotic Disorders. 3 rd ed. New York: Facts on File; 2007. p.20-2.
  31. Phelps L. Psychopharmacology for pediatric neuropsychologists. In: Davis AS, ed. The Handbook of Pediatric Neuropsychology. 1st ed. New York: Springer Publishing Company; 2011. p.1077-85.
  32. Zeller EA, Barsky J, Fouts JR, Kirchheimer WF, Van Orden LS. Influence of isonicotinic acid hydrazide (INH) and 1-isonicotinic-2isopropyl-hydrazide (IIH) on bacterial and mammalian enzymes. Experientia. 1952;8(9): 349-50. [Crossref]
  33. López-Muñoz F, Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des. 2009;15(14):1563-86. [Crossref]
  34. Healy D. The intersection of psychopharmacology and psychiatry in the second half of the twentieth century. In: Wallice ER, Gach J, eds. History of Psychiatry and Medical Psychology: With an Epilogue on Psychiatry. 1st ed. New York: Springer Science+Business Media; 2008. p.XXXI, 424. [Crossref]
  35. Loomer HP, Saunders JC, Kline NS. A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiatr Res Rep Am Psychiatr Assoc. 1957;8:12941.
  36. Shulman KI, Herrmann N, Walker SE. Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs. 2013;27(10):789-97. [Crossref] [PubMed]
  37. Kline NS. Clinical experience with iproniazid (marsilid). J Clin Exp Psychopathol. 1958;19(2 Suppl 1):72-8.
  38. The Albert and Mary Lasker Foundation. 1964 Albert Lasker Clinical Medical Research Award: iproniazid for the treatment of severe depression. Erişim: 8.1.2017. [Link]
  39. Lurie ML, Salzer HM. Tranylcypromine (Parnate) in the ambulatory treatment of depressed patients. Am J Psychiatry. 1961;118: 152-5. [Crossref] [PubMed]
  40. Blackwell B. Hypertensive crisis due to monoamine-oxidase inhibitors. Lancet. 1963;282(7313):849-50. [Crossref]
  41. Dally PJ. Fatal reaction associated with tranylcypromine and methylamphetamine. Lancet. 1962;279:1235-6. [Crossref]
  42. Taylor DC. Alarming reaction to pethidine in patients on phenelzine. Lancet. 1962; 280(7252):401-2. [Crossref]
  43. Bilden BF. Antidepressants. In: Marx JA, Hockberger RS, Walls RM, Adams J, Barsan WG, Biros MH, et al., eds. Rosen?s Emergency Medicine: Concepts and Clinical Practice. 7th ed. St Louis: Mosby; 2010. p.1964-78. [Crossref]
  44. PubChem. ABD Ulusal Sağlık Enstitüleri Ulusal Biyoteknoloji Bilgi Merkezi kimyasal moleküller veri tabanı. Erişim: 20.10.2016. [Link]
  45. Youdim MBH, Sourkes TL. The effect of heat, inhibitors, and riboflavin deficiency on monoamine oxidase. Can J Biochem. 1965;43:1305-18. [Crossref]
  46. Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol. 1968;17(7):1285-97. [Crossref]
  47. Da Prada M, Kettler R, Keller HH, Cesura AM, Richards JG, Saura Marti J, et al. From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J Neural Transm Suppl. 1990;29:279-92. [Crossref] [PubMed]
  48. Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behavior. Annu Rev Neurosci. 1999;22:197-217. [Crossref] [PubMed] [PMC]
  49. Gaweska H, Fitzpatrick PF. Structures and mechanism of the monoamine oxidase family. Biomol Concepts. 2011;2(5):365-77. [Crossref] [PubMed] [PMC]
  50. Lotufo-Neto F, Trivedi M, Thase ME. Metaanalysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999;20(3):226-47. [Crossref]
  51. Knoll J, Ecseri Z, Kelemen K, Nievel J, Knoll B. Phenylisopropylmenthylpropinylamine (E250), a new spectrum psychic energizer. Arch Int Pharmacodyn Ther. 1965;155(1):154-64.
  52. Riederer P, Laux G. MAO-inhibitors in Parkinson?s disease. Exp Neurobiol. 2011;20(1):117. [Crossref] [PubMed] [PMC]
  53. Nagatsu T, Sawada M. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson?s disease: possible implications of glial cells. J Neural Transm Suppl. 2006;71:53-65. [Crossref]
  54. Fernandez HH, Chen JJ. Monoamine oxidase inhibitors: current and emerging agents for Parkinson disease. Clin Neuropharmacol. 2007;30(3):150-68. [Crossref] [PubMed]
  55. Lipper S, Murphy DL, Slater S, Buchsbaum MS. Comparative behavioral effects of clorgy line and pargyline in man: a preliminary evaluation. Psychopharmacology (Berl). 1979;62(2):123-8. [Crossref]
  56. Tural Ü, Önder E. [Pharmacology of reversible monoamine oxidase-a inhibitors]. Klinik Psikiyatri. 2001;(Ek 4):5-11.
  57. O?Connor AD, Mills KC. Monoamine oxidase inhibitors. In: Brent J, Burkhart K, Dargan P, Hatten B, Megarbane B, Palmer R, eds. Critical Care Toxicology. New York: Springer; 2016. p.1-18.
  58. Turner T. Chlorpromazine: unlocking psychosis. BMJ. 2007;334 Suppl 1:s7. [Crossref] [PubMed]
  59. Courvoisier S, Fournel J, Ducrot R, Kolsky M, Koetschet P. [Pharmacodynamic properties of 3-chloro-10-(3-dimethylaminopropyl)phenothiazine hydrochloride (R.P. 4560); experimental study of a new substance used in potentialized anesthesia and in artificial hibernation]. Arch Int Pharmacodyn Ther. 1953;92(3-4):305-61.
  60. Ban TA. Fifty years chlorpromazine: a historical perspective. Neuropsychiatr Dis Treat. 2007;3(4):495-500.
  61. Folsom TD, Merz A, Grant JE, Fatemi N, Fatemi SA, Fatemi SH. Profiles in history of neuroscience and psychiatry. In: Fatemi SH, Clayton PJ, eds. The Medical Basis of Psychiatry. 4th ed. New York: Springer Science+Business Media; 2016. p.925-1008. [Crossref]
  62. López-Muñoz F, Alamo C, Cuenca E, Shen WW, Clervoy P, Rubio G. History of the discovery and clinical ıntroduction of chlorpromazine. Ann Clin Psychiatry. 2005;17(3): 113-35. [Crossref]
  63. Hamon J, Paraire J, Velluz J. [Effect of R.P. 4560 on maniacal agitation]. Ann Med Psychol (Paris). 1952;110(1 3):331-5.
  64. Kuhn R. [Treatment of depressive states with an iminodibenzyl derivate (G22355)]. Schweiz Med Wochenschr. 1957;87(35-36):1135-40.
  65. Brown WA, Rosdolsky M. The clinical discovery of imipramine. Am J Psychiatry. 2015;172(5):426-9. [Crossref] [PubMed]
  66. Kuhn R. The treatment of depressive states with G 22355 (imipramine hydrochloride). Am J Psychiatry. 1958;115(5):459-64. [Crossref] [PubMed]
  67. Shorter E. Glossary. In: Before Prozac: The Troubled History of Mood Disorders in Psychiatry. 1st ed. Oxford: Oxford University Press; 2009. p.215-29.
  68. Lehmann HE, Cahn CH, de Verteuil RL. The treatment of depressive conditions with imipramine (G 22355). Can Psychiatr Assoc J. 1958;3(4):155-64. [Crossref] [PubMed]
  69. Fangmann P, Assion HJ, Juckel G, González CA, López-Muñoz F. Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part II: tricyclics and tetracyclics. J Clin Psychopharmacol. 2008;28(1):1-4. [Crossref] [PubMed]
  70. Paris J. Heinz Lehmann: a pioneer of modern psychiatry. Can J Psychiatry. 1999;44:441-2. [Crossref]
  71. Ayd FJ. Amitriptyline (Elavil) therapy for depressive reactions. Psychosomatics. 1960; 6(1):320-5. [Crossref]
  72. Gottfried R, Frosch E, Riddle M. Antidepressants II: other agents. In: Martin A, Scahill L, Kratochi C, eds. Pediatric Psychopharmacology: Principles and Practice. 2nd ed. Oxford: Oxford University Press; 2011. p.286-96. [Crossref]
  73. Amin M, Brahm E, Bronheim LA, Klingner A, Ban TA, Lehmann HE. A double-blind, comparative clinical trial with ludiomil (CIBA 34,276-Ba) and amitriptyline in newly admitted depressed patients. Curr Ther Res Clin Exp. 1973;15(10):691-9.
  74. Healy D. The trials of therapeutic empiricism. In: The Antidepressant Era. Cambridge (MA/ABD): Harvard University Press; 1997. p.111-43.
  75. Schuckit M, Robins E, Feighner J. Tricyclic antidepressants and monoamine oxidase inhibitors. Arch Gen Psychiatry. 1971;24(6):509-14. [Crossref] [PubMed]
  76. White K, Simpson G. Combined MAOI-tricyclic antidepressant treatment: a reevaluation. J Clin Psychopharmacol. 1981;1(5):264-82. [Crossref] [PubMed]
  77. Lader MH. Combined use of tricyclic antidepressants and monoamine oxidase inhibitors. J Clin Psychiatry 1983;44(9 Pt 2):20-4.
  78. Goldman LS, Alexander RC, Luchins DJ. Monoamine oxidase inhibitors and tricyclic antidepressants: comparison of their cardiovascular effects. J Clin Psychiatry. 1986;47(5): 225-9.
  79. Ryan ND, Puig-Antich J, Rabinovich H, Fried J, Ambrosini P, Meyer V, et al. MAOIs in adolescent major depression unresponsive to tricyclic antidepressants. J Am Acad Child Adolesc Psychiatry. 1988;27(6):755-8. [Crossref] [PubMed]
  80. Roth M, Guelfi JD. The efficacy of reversible monoamine oxidase inhibitors in depressive illness. Can J Psychiatry. 1992;37 Suppl 1:1824.
  81. Temel MK. [The development of cytotoxic chemotherapeutics in the twentieth century]. Türk Onkoloji Derg. 2015;30(2):96-108. [Crossref]
  82. Falck B, Hillarp NA, Thieme G, Torp A. Fluorescence of catechol amines and related compounds condensed with formaldehyde. J Histochem Cytochem. 1962;10:348-54.[Crossref]
  83. Carlsson A. A historical note on the development of zimelidine, the first selective serotonin reuptake inhibitor. Eur Psychiatry. 1996;11 Suppl 4:235s-6s. [Crossref]
  84. Wallenberg Neuroscience Center. The FalckHillarp Method-a revoluation in the study of monoamine systems in the CNS. Erişim: 10.8.2017. [Link]
  85. Carlsson A, Falck B, Hillarp NA. Cellular localization of brain monoamines. Acta Physiol Scand Suppl. 1962;56(196):1-28.
  86. Vos R. The enigma of drug discovery. In: Drugs Looking for Diseases: Innovative Drug Research and the Development of the Beta Blockers and the Calcium Antagonists. 1st ed. New York: Springer Science+Business Media; 1991. p.267-79.
  87. Falck B, Torp A. New evidence for the localization of noradrenalin in the adrenergic nerve terminals. Med Exp Int J Exp Med. 1962;6:169-72. [Crossref] [PubMed]
  88. Shaw DM, Camps FE, Eccleston EG. 5-hydroxytryptamine in the hind-brain of depressive suicides. Br J Psychiatry. 1967;113(505): 1407-11. [Crossref] [PubMed]
  89. Bourne HR, Bunney WE Jr, Colburn RW, Davis JM, Davis JN, Shaw DM, et al. Noradrenaline, 5-hydroxytryptamine, and 5-hydroxyindoleacetic acid in hindbrains of suicidal patients. Lancet. 1968;2(7572):805-8. [Crossref]
  90. Carlsson A. The discovery of the SSRIs: a milestone in neuropsychopharmacology and rational drug design. In: Standford SC, ed. Selective Serotonin Reuptake Inhibitors (SSRIs): Past, Present and Future. Austin (TX/ABD): R.G. Landes Company; 1999. p.1-7.
  91. The Nobel Prizes. The Nobel Prize in Physiology or Medicine 2000. Erişim: 5.2.2018. [Link]
  92. Badiani A. History of psychopharmacology. In: Stolerman I, ed. Encyclopedia of Psychopharmacology. Vol. 1. New York: Springer Science+Business Media; 2010. p.593-603.
  93. Fagius J, Osterman PO, Sidén A, Wiholm BE. Guillain-Barré syndrome following zimeldine treatment. J Neurol Neurosurg Psychiatry. 1985;48(1):65-9. [Crossref] [PubMed] [PMC]
  94. Laaban JP, Lebras P, Dugay J, Texier F, Vayrac A, Renou P, et al. [3 cases of agranulocytosis during polytherapy including indalpine]. Rev Med Interne. 1985;6(4):433-5. [Crossref]
  95. Bogeso KP, Bang-Andersen B. Dopamine and serotonin receptor and transporter ligands. In: Liljefors T, Krogsgaard-Larsen P, Madsen U, eds. Textbook of Drug Design and Discovery. 3rd ed. New York: Taylor & Francis; 2002. p.366-78.
  96. Wong DT, Horng JS, Bymaster FP, Hauser KL, Molloy BB. A selective inhibitor of serotonin uptake: lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sci. 1974; 15(3):471-9. [Crossref]
  97. Wong DT, Perry KW, Bymaster FP. The discovery of fluoxetine hydrochloride (Prozac). Nat Rev Drug Discov. 2005;4(6):764-74. [Crossref] [PubMed]
  98. Wenthur CJ, Bennett MR, Lindsley CW. Classics in chemical neuroscience: fluoxetine (Prozac). ACS Chem Neurosci. 2013;5(1):14-23. [Crossref] [PMC]
  99. Stossel S. Medication and the meaning of anxiety. In: My Age of Anxiety: Fear, Hope, Dread, and the Search for Peace of Mind. 1st ed. New York: Knopf Doubleday Publishing Group; 2014. p.200-28.
  100. Placheta P, Singer E, Kriwanek W, Hertting G. Mepiprazole, a new psychotropic drug: effects on uptake and retention of monoamines in rat brain synaptosomes. Psychopharmacology (Berl). 1976;48(3):295-301. [Crossref]
  101. Fagiolini A, Comandini A, Catena Dell?Osso M, Kasper S. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012;26(12):1033-49. [Crossref] [PubMed] [PMC]
  102. Taciak PP, Lysenko N, Mazurek AP. Drugs which influence serotonin transporter and serotonergic receptors: pharmacological and clinical properties in the treatment of depression. Pharmacol Rep. 2018;70(1):37-46. [Crossref] [PubMed]
  103. Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015;145:43-57. [Crossref] [PubMed]
  104. Lundbeck. Brintellix® (vortioxetine) fact sheet. Erişim: 7.2.2018. [Link]
  105. Mendlewicz J. Pharmacologic profile and efficacy of venlafaxine. Int Clin Psychopharmacology. 1995;10 Suppl 2:5-13. [Crossref] [PubMed]

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com